Aethlon Medical reports Q3 net loss of $2.85M; cash $17.5M; hires Lee Arnold as CSO

AETHLON MEDICAL INC

2023-Q3 EPS reported -$0.48

Net loss increased to ~$2.85M for quarter vs $2.53M year ago; operating expenses rose 12% to $2.85M.
Cash balance ~$17.5M at Dec 31, 2022; raised $8.9M net via ATM equity offers in nine fiscal months.
Hired Lee Arnold, PhD (inventor of Tarceva) as Chief Scientific Officer; contracted NAMSA for planned oncology Hemopurifier trial.
COVID-19 ICU trial in India continues (one patient treated); preclinical mPox and Long COVID studies underway.
No government contract revenue recorded; $574K deferred revenue expected after NCI closeout review.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AETHLON MEDICAL INC reported third quarter ended December 31, 2022 results: net income approximately $2,850,000.

Period: third quarter ended December 31, 2022
Net income: approximately $2,850,000
Result: reported results

Exact text from the filing

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its third quarter ended December 31, 2022

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

AETHLON MEDICAL INC filing history →

Source: SEC EDGAR

accession 0001683168-23-000813

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.